SAR440340

anti-IL-33 monoclonal antibody · Sanofi

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for SAR440340, covering 2022-03-29 to 2026-04-15. Get the full timeline:

Most recent: Clinical Trial Update: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

See pricing